September 20, 2011
A 24-week course of treatment for chronic hepatitis C virus (HCV) infection that added telaprevir to peginterferon and ribavirin was just as effective as a 48-week regimen for many patients in the current study.
This multicenter research enrolled 540 treatment-naïve patients with chronic infection with HCV genotype 1. All received telaprevir (Incivek), peginterferon alfa-2a and ribavirin for 12 weeks, after which telaprevir was suspended.
Patients who had an extended rapid virologic response (ERVR) (undetectable HCV RNA levels at weeks 4 and 12) were randomly assigned, after week 20, to receive dual therapy for four more weeks (24-week group) or for 28 more weeks (48-week group). Patients without ERVR were assigned to the 48-week group.
"In this study, among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with undetectable HCV RNA at weeks 4 and 12, with [ERVR] achieved in nearly two-thirds of patients," the authors concluded.
New England Journal of Medicine
09.15.2011; Vol. 365: P. 1014-1024; Kenneth E. Sherman, M.D., Ph.D., and others
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|